Sorafenib in advanced hepatocellular carcinoma

Cited by (1,037)

Items 701–800 of 1,037

1. Retreatment with TACE: The ABCR SCORE, an aid to the decision-making process
   Xavier Adhoute, Guillaume Pénaranda, Sébastien Naudé, Jean‐Luc Raoul, Hervé Perrier, Olivier Bayle, O. Monnet, Patrick Beaurain, Christophe Bazin, Bernard Pol et al. · 2014 · Journal of Hepatology
2. Early alpha‐fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma
   Yu‐Yun Shao, Zhong‐Zhe Lin, Chiun Hsu, Ying‐Chun Shen, Chih-Hung Hsu, Ann‐Lii Cheng · 2010 · Cancer
3. Hepatic stellate cells and extracellular matrix in hepatocellular carcinoma: more complicated than ever
   Vinicio Carloni, Tu Vinh Luong, Krista Rombouts · 2014 · Liver International
4. The Adverse Effects of Sorafenib in Patients with Advanced Cancers
   Ye Li, Zu‐Hua Gao, Xian‐Jun Qu · 2014 · Basic & Clinical Pharmacology & Toxicology
5. Deferoxamine for Advanced Hepatocellular Carcinoma
   Takahiro Yamasaki, Shuji Terai, Isao Sakaida · 2011 · New England Journal of Medicine
6. Sorafenib Overcomes TRAIL Resistance of Hepatocellular Carcinoma Cells through the Inhibition of STAT3
   Kuen‐Feng Chen, Wei‐Tien Tai, Tsung‐Hao Liu, Hsiang–Po Huang, Yu-Chin Lin, Chung‐Wai Shiau, Pui‐Kai Li, Pei‐Jer Chen, Ann‐Lii Cheng · 2010 · Clinical Cancer Research
7. Hepatitis C virus-induced hepatocellular carcinoma
   Nicolas Goossens, Yujin Hoshida · 2015 · Clinical and Molecular Hepatology
8. Systemic Therapy for Hepatocellular Carcinoma: Latest Advances
   Masatoshi Kudo · 2018 · Cancers
9. Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals
   Shira Perez, Antony Kaspi, Tom Domovitz, Ateret Davidovich, Anat Lavi-Itzkovitz, Tomer Meirson, Jacinta Alison Holmes, Chia‐Yen Dai, Chung‐Feng Huang, Raymond T. Chung et al. · 2019 · PLoS Genetics
10. Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions
    Marc Hilmi, Cindy Neuzillet, Julien Caldéraro, Fouad Lafdil, Jean–Michel Pawlotsky, Benoı̂t Rousseau · 2019 · Journal for ImmunoTherapy of Cancer
11. Low-Dose Sorafenib Acts as a Mitochondrial Uncoupler and Ameliorates Nonalcoholic Steatohepatitis
    Chongshu Jian, Jiajun Fu, Xu Cheng, Lijun Shen, Yan‐Xiao Ji, Xiaoming Wang, Shan Pan, Han Tian, Song Tian, Rufang Liao et al. · 2020 · Cell Metabolism
12. Inhibiting the VEGF–VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/solitary fibrous tumor
    Min S Park, Vinod Ravi, Dejka M. Araujo · 2010 · Current Opinion in Oncology
13. Current and future treatments for hepatocellular carcinoma
    Alexander Schlachterman · 2015 · World Journal of Gastroenterology
14. Real-World Evidence in Oncology: Opportunities and Limitations
    Massimo Di Maïo, Francesco Perrone, PierFranco Conte · 2019 · The Oncologist
15. A Phase I First-in-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients with Advanced Cancer
    Lee S. Rosen, Herbert I. Hurwitz, Michael K. Wong, Jonathan Wade Goldman, David S. Mendelson, William Douglas Figg, Shawn D. Spencer, Bonne J. Adams, Delia Alvarez, Ben K. Seon et al. · 2012 · Clinical Cancer Research
16. Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: Treatment with Transarterial Chemoembolization Combined with Sorafenib—A Retrospective Controlled Study
    Kangshun Zhu, Junwei Chen, Lisha Lai, Xiaochun Meng, Bin Zhou, Wensou Huang, Mingyue Cai, Hong Shan · 2014 · Radiology
17. Targeted therapy for hepatocellular carcinoma: novel agents on the horizon
    Melchiorre Cervello, James Andrew McCubrey, Antonella Cusimano, Nadia Lampiasi, Antonina Azzolina, Giuseppe Montalto · 2012 · Oncotarget
18. Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells
    Martin Franz Sprinzl, Florian Reisinger, Andreas S. Puschnik, Marc Ringelhan, Kerstin Ackermann, Daniel Hartmann, Matthias Schiemann, Arndt Weinmann, Peter R. Galle, Marcus Schuchmann et al. · 2013 · Hepatology
19. Profile of Tumor Antigen-Specific CD8 T Cells in Patients With Hepatitis B Virus-Related Hepatocellular Carcinoma
    Adam J. Gehring, Zi Zong Ho, Anthony Tanoto Tan, Myat Oo Aung, Kang Hoe Lee, Kai Chah Tan, Seng Gee Lim, Antonio Bertoletti · 2009 · Gastroenterology
20. MicroRNA-93 activates c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by directly inhibiting PTEN and CDKN1A
    Katsuya Ohta, Hiromitsu Hoshino, Jinhua Wang, Shigeshi Ono, Yuuki Iida, Keisuke Hata, Sharon K. Huang, Steven D. Colquhoun, Dave S.�B. Hoon · 2014 · Oncotarget
21. Cardiotoxicity Associated with Targeting Kinase Pathways in Cancer
    Howard R. Mellor, Alex R. Bell, Jean‐Pierre Valentin, Ruth R.A. Roberts · 2010 · Toxicological Sciences
22. Improving Oral Bioavailability of Sorafenib by Optimizing the “Spring” and “Parachute” Based on Molecular Interaction Mechanisms
    Chengyu Liu, Zhen Chen, Yuejie Chen, Jia En Lu, Yuan Li, Shujing Wang, Guoliang Wu, Feng Qian · 2015 · Molecular Pharmaceutics
23. ACSL4 is a predictive biomarker of sorafenib sensitivity in hepatocellular carcinoma
    Feng Ji, Pei-zhi Lu, Guangzhi Zhu, Shing Chuan Hooi, Yong Wu, Xiaowei Huang, Hui-Qi Dai, Pan-hong Chen, Zhongjie Li, Wenjing Su et al. · 2020 · Acta Pharmacologica Sinica
24. The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT)
    Marta Scorsetti, Tiziana Comito, Luca Cozzi, Elena Clerici, A. Tozzi, Ciro Franzese, Pierina Navarria, Antonella Fogliata, Stefano Tomatis, Giuseppe Roberto D’Agostino et al. · 2015 · Journal of Cancer Research and Clinical Oncology
25. Anti-hepatocellular carcinoma activity using human HepG2 cells and hepatotoxicity of 6-substituted methyl 3-aminothieno[3,2-b]pyridine-2-carboxylate derivatives: In vitro evaluation, cell cycle analysis and QSAR studies
    Rui M.V. Abreu, Isabel C.F.R. Ferreira, Ricardo Costa Calhelha, Raquel T. Lima, M. Helena Vasconcelos, Filomena Adega, Raquel Chaves, Maria João R.P. Queiroz · 2011 · European Journal of Medicinal Chemistry
26. Surgical treatment of hepatocellular carcinoma associated with hepatic vein tumor thrombosis
    Takashi Kokudo, Kiyoshi Hasegawa, Satoshi Yamamoto, Junichi Shindoh, Nobuyuki Takemura, Taku Aoki, Yoshihiro Sakamoto, Masatoshi Makuuchi, Yasuhiko Sugawara, Norihiro Kokudo · 2014 · Journal of Hepatology
27. The Price We Pay for Progress: A Meta-Analysis of Harms of Newly Approved Anticancer Drugs
    Saroj Niraula, Boštjan Šeruga, Alberto Ocaña, Tiffany Shao, Robyn Goldstein, Ian F. Tannock, Eitan Amir · 2012 · Journal of Clinical Oncology
28. Nivolumab for the treatment of hepatocellular carcinoma
    Fabian Finkelmeier, Oliver Waidmann, Joerg Trojan · 2018 · Expert Review of Anticancer Therapy
29. MicroRNA-342-3p is a potent tumour suppressor in hepatocellular carcinoma
    Ronja‐Melinda Komoll, Qingluan Hu, Olaniyi Olarewaju, Lena von Döhlen, Qinggong Yuan, Yu Xie, Hsin-Chieh Tsay, Joel Daon, Renyi Qin, Michael Peter Manns et al. · 2020 · Journal of Hepatology
30. Signaling pathways in hepatocellular carcinoma
    Teresa García‐Lezana, Juan Luis Lopez-Canovas, Augusto Villanueva · 2020 · Advances in cancer research
31. Current management of hepatocellular carcinoma
    Parissa Tabrizian · 2014 · World Journal of Gastroenterology
32. The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond
    Seth Andrew Wander, Mark J. Levis, Amir T. Fathi · 2014 · Therapeutic Advances in Hematology
33. Advances in Cancer Immunotherapy in Solid Tumors
    Smitha Patiyil Menon, Sarah J. Shin, Grace Kho Dy · 2016 · Cancers
34. Histone methyltransferase G9a promotes liver cancer development by epigenetic silencing of tumor suppressor gene RARRES3
    Lai Wei, David Kung‐Chun Chiu, Felice Ho‐Ching Tsang, Cheuk‐Ting Law, Carol Lai‐Hung Cheng, Sandy Leung–Kuen Au, Joyce Man‐Fong Lee, Carmen Chak‐Lui Wong, Chun‐Ming Wong, Chun‐Ming Wong · 2017 · Journal of Hepatology
35. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma
    Rui Xing, Jinping Gao, Qi Cui, Qian Wang · 2021 · Frontiers in Immunology
36. Cardiac Toxicity From Systemic Cancer Therapy: A Comprehensive Review
    Giuseppe Curigliano, Erica L. Mayer, Harold J. Burstein, Eric P. Winer, Aron Goldhirsch · 2010 · Progress in Cardiovascular Diseases
37. Harnessing big ‘omics’ data and AI for drug discovery in hepatocellular carcinoma
    Chen, Bin, Garmire, Lana, Calvisi, Diego F., Chua, Mei-Sze, Kelley, Robin K., Chen, Xin · 2020 · Nature Reviews Gastroenterology & Hepatology
38. Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast Cancer
    Jose M Baselga, J. G. M. Segalla, Henri Hubert Roche, Auro del Giglio, Hélio Pinczowski, Eva Ciruelos, Sebastião Cabral Filho, Patricia Gómez, Brigitte Van Eyll, Begoña Bermejo et al. · 2012 · Journal of Clinical Oncology
39. VHL gene mutations in renal cell carcinoma: Role as a biomarker of disease outcome and drug efficacy
    C. Lance Cowey, W. Kimryn Rathmell · 2009 · Current Oncology Reports
40. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways
    Yanmin Xu, Ji Huang, Leina Ma, Juanjuan Shan, Junjie Shen, Zhi Yang, Limei Liu, Yongli Luo, Chao Yao, Cheng Qian · 2015 · Cancer Letters
41. Optimized RNA-targeting CRISPR/Cas13d technology outperforms shRNA in identifying functional circRNAs
    Yang Zhang, Tuan M. Nguyen, Xiao-Ou Zhang, Limei Wang, Tin Phan, John G. Clohessy, Pier Paolo Pandolfi · 2021 · Genome biology
42. MicroRNAs in liver cancer: a model for investigating pathogenesis and novel therapeutic approaches
    Elisa Callegari, Laura Gramantieri, Marco Domenicali, Lucilla D’Abundo, Silvia Sabbioni, Massimo Negrini · 2014 · Cell Death and Differentiation
43. Up‐regulation of histone methyltransferase SETDB1 by multiple mechanisms in hepatocellular carcinoma promotes cancer metastasis
    Chun‐Ming Wong, Lai Wei, Cheuk‐Ting Law, Daniel Wai‐Hung Ho, Felice Ho‐Ching Tsang, Sandy Leung–Kuen Au, Karen Man‐Fong Sze, Joyce Man‐Fong Lee, Carmen Chak‐Lui Wong, Irene Oi‐Lin Ng · 2015 · Hepatology
44. The Function of the HGF/c-Met Axis in Hepatocellular Carcinoma
    Haiyu Wang, Benchen Rao, Jiamin Lou, Jianhao Li, Zhenguo Liu, Ang Li, Guangying Cui, Zhigang Ren, Zujiang Yu · 2020 · Frontiers in Cell and Developmental Biology
45. International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma
    Amit G. Singal, Yujin Hoshida, David James Pinato, Jorge A. Marrero, Jean‐Charles Nault, Valérie Paradis, Nabihah Tayob, Morris Sherman, Young‐Suk Lim, Ziding Feng et al. · 2021 · Gastroenterology
46. Immunomodulatory Effects of Lenvatinib Plus Anti–Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma
    Laura Torrens, Carla Montironi, Marc Puigvehí, Agavni Mesropian, Jack Leslie, Philipp Konstantin Haber, Miho Maeda, Ugne Balaseviciute, Catherine E. Willoughby, Jordi Abril‐Fornaguera et al. · 2021 · Hepatology
47. Management of hepatocellular carcinoma: Report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009)
    Shigeki Arii, Michio Sata, Michiie Sakamoto, Mitsuo Shimada, Takashi Kumada, Shuichiro Shiina, Tatsuya Yamashita, Norihiro Kokudo, Masatoshi Tanaka, Tadatoshi Takayama et al. · 2010 · Hepatology Research
48. MicroRNA-34a Targets Bcl-2 and Sensitizes Human Hepatocellular Carcinoma Cells to Sorafenib Treatment
    Fan Yang, Qing-jun Li, Zhen-bin Gong, Liang Zhou, Nan You, Su Wang, Xiaolei Li, Junjie Li, Jiaze An, Desheng Wang et al. · 2013 · Technology in Cancer Research & Treatment
49. Targeting MET in cancer therapy
    Hongnan Mo, Peng Liu · 2017 · Chronic Diseases and Translational Medicine
50. Breakthroughs in Hepatocellular Carcinoma Therapies
    Amit G. Singal, Masatoshi Kudo, Jordi Bruix · 2023 · Clinical Gastroenterology and Hepatology
51. Critical Appraisal of Guideline Recommendations on Systemic Therapies for Advanced Hepatocellular Carcinoma: A Review
    Cappuyns, Sarah, Corbett, Virginia, Yarchoan, Mark, Finn, Richard S., Llovet, Josep M. · 2024 · JAMA Oncology
52. Preclinical Rationale for Use of the Clinically Available Multitargeted Tyrosine Kinase Inhibitor Crizotinib in ROS1-Translocated Lung Cancer
    Hiroyuki Yasuda, Lorena Lobo de Figueiredo‐Pontes, Susumu S. Kobayashi, Daniel Botelho Costa · 2012 · Journal of Thoracic Oncology
53. MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity
    Lei‐Bo Xu, Susanne Beckebaum, Speranța Iacob, Gang Wu, Gernot M. Kaiser, Arnold Radtke, Chao Liu, Iyad Kabar, Hartmut Schmidt, Xiaoyong Zhang et al. · 2013 · Journal of Hepatology
54. Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma
    Joseph Ralph Kallini, Ahmed Gabr, Riad Salem, Robert J. Lewandowski · 2016 · Advances in Therapy
55. Do patient access schemes for high-cost cancer drugs deliver value to society?—lessons from the NHS Cancer Drugs Fund
    Ajay Kumar Aggarwal, Tito Fojo, Charlotte Chamberlain, Courtney Davis, Richard J. Sullivan · 2017 · Annals of Oncology
56. Immunotherapy of hepatocellular carcinoma
    Angela D. Pardee, Lisa Helene Butterfield · 2012 · OncoImmunology
57. Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma
    Joong‐Won Park, Young Hwan Koh, Hyun Beom Kim, Hwi Young Kim, Sangbu An, Joon‐Il Choi, Sang Myung Woo, Byung‐Ho Nam · 2012 · Journal of Hepatology
58. αB-crystallin complexes with 14-3-3ζ to induce epithelial-mesenchymal transition and resistance to sorafenib in hepatocellular carcinoma
    Xiaoyong Huang, Ai‐Wu Ke, Guo‐Ming Shi, Xin Zhang, Chi Zhang, Ying–Hong Shi, Xiaoying Wang, Zhen‐Bin Ding, Yongsheng Xiao, Jun Yan et al. · 2013 · Hepatology
59. Efficacy and Safety of Sorafenib in Combination With Mammalian Target of Rapamycin Inhibitors for Recurrent Hepatocellular Carcinoma After Liver Transplantation
    Carlos Gómez-Martín, Javier Bustamante, J.F. Castroagudı́n, Magdalena Salcedo, Elena Garralda, Milagros Testillano, Ignacio Herrero, Ana María Matilla, Bruno Sangro · 2011 · Liver Transplantation
60. SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma
    Anthony B. El-Khoueiry, Cathryn J. Rankin, Edgar Ben‐Josef, Heinz‐Josef Lenz, Philip Jordan Gold, Robert D. Hamilton, Rangaswamy Govindarajan, Cathy Eng, Charles David Blanke · 2011 · Investigational New Drugs
61. MicroRNAs regulate methionine adenosyltransferase 1A expression in hepatocellular carcinoma
    Heping Yang, Michele E. Cho, Tony W.H. Li, Hui Peng, Kwang Suk Ko, José María Mato, Shelly Chi-Loo Lu · 2012 · Journal of Clinical Investigation
62. Hepatic stem cells and transforming growth factor β in hepatocellular carcinoma
    Avijit Majumdar, Steven A. Curley, Xifeng Wu, Powel H. Brown, Jessica Park Hwang, Kirti Shetty, Zhixing Yao, Aiwu Ruth He, Shulin Li, Lior Haim Katz et al. · 2012 · Nature Reviews Gastroenterology & Hepatology
63. MiRNA199a-3p suppresses tumor growth, migration, invasion and angiogenesis in hepatocellular carcinoma by targeting VEGFA, VEGFR1, VEGFR2, HGF and MMP2
    Alip Ghosh, Debanjali Dasgupta, Amit Kumar Ghosh, Shrabasti Roychoudhury, Dhiraj Kumar, Mahadeo Gorain, Ramesh Butti, Simanti Datta, Shaleen K. Agarwal, Subhash Chandra Gupta et al. · 2017 · Cell Death and Disease
64. A New Treatment Option for Intermediate-Stage Hepatocellular Carcinoma with High Tumor Burden: Initial Lenvatinib Therapy with Subsequent Selective TACE
    Masatoshi Kudo · 2019 · Liver Cancer
65. Role of Wnt/Beta-Catenin Signaling in Liver Metabolism and Cancer
    S. Monga · 2009 · International Journal of Biochemistry and Cell Biology
66. Role of radiotherapy in the management of hepatocellular carcinoma: A systematic review
    Μaria-Aggeliki Kalogeridi · 2015 · World Journal of Hepatology
67. A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients
    TS Yang, SN Lu, Yee Chao, I.-Shyan Sheen, C-C. Lin, T. Wang, S-C Chen, JH Wang, L-Y Liao, J A Thomson et al. · 2010 · British Journal of Cancer
68. FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation
    Jingshan Tong, Shuai Tan, Fangdong Zou, Jian Yu, Lin Zhang · 2016 · Oncogene
69. Review article: systemic treatment of hepatocellular carcinoma
    Matthias Pinter, Markus Peck‐Radosavljevic · 2018 · Alimentary Pharmacology & Therapeutics
70. Pediatric hepatocellular carcinoma
    Rajeev Khanna, Sanjeev Kumar Verma · 2018 · World Journal of Gastroenterology
71. Combined Antitumor Effects of Sorafenib and GPC3-CAR T Cells in Mouse Models of Hepatocellular Carcinoma
    Xiuqi Wu, Hong Luo, Bizhi Shi, Shengmeng Di, Ruixin Sun, Jingwen Su, Ying Liu, Hua Li, Hua Jiang, Zonghai Li · 2019 · Molecular Therapy
72. Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-Of-Concept Study
    Masatoshi Kudo, Tomoko Aoki, Kazuomi Ueshima, Kaoru Tsuchiya, Masahiro Morita, Hirokazu Chishina, Masahiro Takita, Satoru Hagiwara, Yasunori Minami, Hiroshi Ida et al. · 2023 · Liver Cancer
73. The multifaceted activity of VEGF in angiogenesis – Implications for therapy responses
    Stijn Moens, Jermaine Goveia, Peter Conrad Stapor, Anna Rita Cantelmo, Peter Carmeliet · 2014 · Cytokine & Growth Factor Reviews
74. A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer
    Andrew Xiuxuan Zhu, Richard S. Finn, Mary F. Mulcahy, Jayne Gurtler, Weijing Sun, Jonathan D. Schwartz, Rita P. Dalal, Adarsh Joshi, Rebecca R. Hozak, Yihuan Xu et al. · 2013 · Clinical Cancer Research
75. Current management of hepatocellular carcinoma.
    Ana Maria Crissien, Catherine T Frenette · 2014 · Europe PMC (PubMed Central)
76. Randomized, Double-Blind, Placebo-Controlled, Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non–Small-Cell Lung Cancer
    David Robert Spigel, Howard A. Burris, F. Anthony Greco, Dianna L. Shipley, Elke K. Friedman, David Michael Waterhouse, Robert C. Whorf, R. Brian Mitchell, Davey B. Daniel, Jeffrey Zangmeister et al. · 2011 · Journal of Clinical Oncology
77. Gene-expression signature of vascular invasion in hepatocellular carcinoma
    Beatriz Mínguez, Yujin Hoshida, Augusto Villanueva, Sara Toffanin, Laia Cabellos, Swan N. Thung, John Mandeli, Daniela Sia, Craig April, Jian‐Bing Fan et al. · 2011 · Journal of Hepatology
78. Liver Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells
    Germana Castelli, Elvira Pelosi, Ugo Testa · 2017 · Cancers
79. Sorafenib Plus Hepatic Arterial Infusion Chemotherapy versus Sorafenib for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis: A Randomized Trial
    Kanglian Zheng, Xu Zhu, Shijie Fu, Guang Cao, Wenqing Li, Liang Xu, Hui Chen, Di Wu, Renjie Yang, Kun Wang et al. · 2022 · Radiology
80. Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma
    Wei‐Tien Tai, Ann‐Lii Cheng, Chung‐Wai Shiau, Hsiang–Po Huang, Jui‐Wen Huang, Pei‐Jer Chen, Kuen‐Feng Chen · 2011 · Journal of Hepatology
81. Molecular mechanisms of sorafenib action in liver cancer cells
    Melchiorre Cervello, Dimcho R Bachvarov, Nadia Lampiasi, Antonella Cusimano, Antonina Azzolina, James Andrew McCubrey, Giuseppe Montalto · 2012 · Cell Cycle
82. Inhibition of Enhancer of zeste homolog 2 (EZH2) induces natural killer cell-mediated eradication of hepatocellular carcinoma cells
    Suresh Bugide, Michael R. Green, Narendra Wajapeyee · 2018 · Proceedings of the National Academy of Sciences
83. Cyclin A2/E1 activation defines a hepatocellular carcinoma subclass with a rearrangement signature of replication stress
    Quentin Bayard, Léa Meunier, Camille Péneau, Victor Renault, Jayendra Shinde, Jean‐Charles Nault, Iadh Mami, Gabrielle Couchy, Giuliana Amaddeo, Emmanuel Tubacher et al. · 2018 · Nature Communications
84. Biological impact and therapeutic perspective of targeting PI3K/Akt signaling in hepatocellular carcinoma: Promises and Challenges
    Mahshid Deldar Abad Paskeh, Fatemeh Ghadyani, Mehrdad Hashemi, Alireza Abbaspour, Amirhossein Zabolian, Salar Javanshir, Mehrnaz Razzazan, Sepideh Mirzaei, Maliheh Entezari, Mohammad Ali Shekhi Beig Goharrizi et al. · 2022 · Pharmacological Research
85. Insulin-Like Growth Factor-1 Receptor Inhibition Induces a Resistance Mechanism via the Epidermal Growth Factor Receptor/HER3/AKT Signaling Pathway: Rational Basis for Cotargeting Insulin-Like Growth Factor-1 Receptor and Epidermal Growth Factor Receptor in Hepatocellular Carcinoma
    Christèle Desbois‐Mouthon, Aurore Baron, Marie-José Blivet-Van Eggelpoël, Lætitia Fartoux, Corinne Venot, Friedhelm Bladt, Chantal Housset, Olivier Rosmorduc · 2009 · Clinical Cancer Research
86. Combined Functional Genome Survey of Therapeutic Targets for Hepatocellular Carcinoma
    Reiko Satow, Miki Shitashige, Yae Kanai, Fumitaka Takeshita, Hidenori Ojima, Takafumi Jigami, Kazufumi Honda, Tomoo Kosuge, Takahiro Ochiya, Setsuo Hirohashi et al. · 2010 · Clinical Cancer Research
87. Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges
    Ganlu Deng · 2015 · World Journal of Hepatology
88. A Natural CCR2 Antagonist Relieves Tumor-associated Macrophage-mediated Immunosuppression to Produce a Therapeutic Effect for Liver Cancer
    Wenbo Yao, Qian Ba, Xiaoguang Li, Hui‐Liang Li, Shoude Zhang, Ya Yuan, Feng Wang, Xiaohua Duan, Jingquan Li, Weidong Zhang et al. · 2017 · EBioMedicine
89. Staging systems of hepatocellular carcinoma: A review
    Sreeshma Tellapuri, Patrick D. Sutphin, Muhammad Shaalan Beg, Amit G. Singal, Sanjeeva Prasad Kalva · 2018 · Indian Journal of Gastroenterology
90. Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysis
    Atsushi Hiraoka, Takashi Kumada, Masanori Atsukawa, Masashi Hirooka, Kunihiko Tsuji, Toru Ishikawa, Koichi Takaguchi, Kazuya Kariyama, Ei Itobayashi, Kazuto Tajiri et al. · 2019 · Cancer Medicine
91. FGF19–FGFR4 Signaling in Hepatocellular Carcinoma
    Aroosha Raja, Inkeun Park, Farhan Ul Haq, Sung‐Min Ahn · 2019 · Cells
92. Diaryl Ether: A Privileged Scaffold for Drug and Agrochemical Discovery
    Tao Chen, Hao Xiong, Jing‐Fang Yang, Xiao‐Lei Zhu, Ren‐Yu Qu, Guang‐Fu Yang · 2020 · Journal of Agricultural and Food Chemistry
93. Angiogenesis in hepatocellular carcinoma: mechanisms and anti-angiogenic therapies
    Changyu Yao, Shilun Wu, Jian Kong, Yiwen Sun, Yannan Bai, Ruhang Zhu, Zhuxin Li, Wenbing Sun, Lemin Zheng · 2023 · Cancer Biology and Medicine
94. Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a meta-analysis
    Tong‐Chun Xue, Xiaoying Xie, Lan Zhang, Xin Hua Yin, Boheng Zhang, Zhenggang Ren · 2013 · BMC Gastroenterology
95. Transarterial Chemoembolization Plus Sorafenib: A Sequential Therapeutic Scheme for HCV-Related Intermediate-Stage Hepatocellular Carcinoma: A Randomized Clinical Trial
    Domenico Ettore Sansonno, Gianfranco Lauletta, Sabino Russi, Vincenza Conteduca, Loredana Sansonno, Franco Dammacco · 2012 · The Oncologist
96. Alternative Response Criteria (Choi, European Association for the Study of the Liver, and Modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib
    Maxime Ronot, Mohamed Bouattour, Johanna Wassermann, Onorina Bruno, Chantal Dreyer, Béatrice Larroque, Laurent Castéra, Valérie Vilgrain, Jacques Belghiti, Éric Raymond et al. · 2014 · The Oncologist
97. Carcinogenesis on the background of liver fibrosis: Implications for the management of hepatocellular cancer
    Joanne Marie O’Rourke, Vandana Sagar, Tahir Shah, Shishir Shetty · 2018 · World Journal of Gastroenterology
98. Macrophages and hepatocellular carcinoma
    Zhiqiang Tian, Xiao-juan Hou, Wen-Ting Liu, Zhi-Peng Han, Li-Xin Wei · 2019 · Cell & Bioscience
99. Prediction of Posthepatectomy Recurrence of Hepatocellular Carcinoma by Circulating Cancer Stem Cells
    Sheung Tat Fan, Zhen Fan Yang, David W. Ho, Michael N.P. Ng, Wan Ching Yu, John Wong · 2011 · Annals of Surgery
100. Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumours
     Devalingam Mahalingam, George Wilding, Samuel Ray Denmeade, J. Sarantopoulas, David Cosgrove, Jeremy Paul Cetnar, Nilofer Saba Azad, Justine Y. Bruce, Michael R. Kurman, Victoria Allgood et al. · 2016 · British Journal of Cancer